Leon nanodrugs
Financials
Estimates*
EUR | 2019 | 2020 | 2021 |
---|---|---|---|
Profit | (2.9m) | (2.7m) | (3.8m) |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€18.5m | Series A | ||
* | N/A | Series B | |
Total Funding | $20.4m |
Related Content
Recent News about Leon nanodrugs
EditLeon-nanodrugs GmbH is a Munich-based company specializing in nanotechnology for the pharmaceutical industry. The company revitalizes forgotten formulations, breathes new life into generics, and expedites active pharmaceutical ingredients (APIs) to deliver enhanced bioavailability, increased solubility, and improved stability. Leon-nanodrugs serves pharmaceutical companies looking to improve the efficacy and stability of their drug formulations. Operating in the highly specialized nanotechnology market, the company leverages its proprietary technology to create value for its partners and address unmet medical needs. The business model revolves around providing novel, ready-to-use, validated nano solutions that enhance the performance of pharmaceutical products. Revenue is generated through partnerships, licensing agreements, and service contracts with pharmaceutical companies.
Keywords: nanotechnology, pharmaceuticals, bioavailability, solubility, stability, formulations, generics, APIs, drug development, Munich.